As the immunotherapy is on progressive development in cancer treatment, it is peremptory that these patients should have their immune system restored to provide a viable therapeutic option; nowadays there are ongoing some clinical trials using anti-CTLA-4 drugs such as ipilimumab in nonimmunosuppressed patients.8 Here, CTLA4 is linked to cancer.